Abstract

The aim of this study was to assess the prevalence of cardiovascular risk factors in TAK, to describe the use of aspirin and statins and the risk factors associated with vascular ischemic complications and relapses. We conducted a retrospective study on TAK patients diagnosed between 2010 and 2018. Demographic, clinical, laboratory data and treatments were evaluated at diagnosis and during the follow-up. We included fifty-two TAK patients with median age 37.5 years [range 16–53] and 43 (83%) women. At diagnosis, cardiovascular risk factors were present in 32 (62%) patients: hypertension (n = 20, 38%), hyperlipidemia (n = 8, 15%), tobacco use (n = 16, 31%). During the median 4-year follow-up [range 0.1–17 years], 17 (33%) patients had at least one ischemic event and 15 (29%) patients needed endovascular procedure. Whereas TAK patients with cardiovascular risk factors were more frequently on statins and anti-hypertensive drugs, they have higher rates of cumulative ischemic complications (5 (24%) versus 21 (67%); p = 0.004), but similar rates of aspirin-treated patients. Patients who have developed vascular ischemic events were more frequently smokers (53% versus 20%; p = 0.03). The vascular complication-free survival was not significantly different in TAK patients with or without statins or aspirin at diagnosis. During the follow-up, 27 (52%) patients had at least one relapse, and the relapse-free survival was not significantly different in patients treated with statins or aspirin. Cardiovascular risk factors in TAK have to be strictly controlled since these risk factors could be associated with increased risk of ischemic complications.

Details

Title
Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis
Author
Laurent, Charlotte 1 ; Prieto-González, Sergio 2 ; Belnou Pierre 3 ; Carrat Fabrice 3 ; Fain, Olivier 1 ; Dellal Azeddine 4 ; Cid, Maria C 2 ; Hernández-Rodríguez José 2 ; Mekinian Arsène 1 

 Sorbonne Université, AP-HP, Service de Médecine Interne and Inflammation-Immunopathology-Biotherapy Department (DMU i3), Hôpital Saint-Antoine, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657) 
 University of Barcelona, Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic of Barcelona, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (GRID:grid.5841.8) (ISNI:0000 0004 1937 0247) 
 Sorbonne Universités, INSERM, Institut Pierre Louis d’épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657); Assistance Publique-Hôpitaux de Paris, Unité de Santé Publique, Hôpital Saint Antoine, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109) 
 Hôpital Montfermeil, Service de Rhumatologie, Montfermeil, France (GRID:grid.462844.8) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2550943924
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.